Posts Tagged: Michael Julius

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy. This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views. The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck ... Read more

WaveCheck breast cancer technology receives $100,000

OICR's catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May TORONTO, April 8, 2014 -- People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last ... Read more

WaveCheck crowdfunding campaign honours contriburing artists, sponsors and inventors

Reception at Sunnybrook Hospital recognizes WaveCheck's inventors, contributing artists and the three women featured in the campaign video The WaveCheck Indiegogo campaign continues to generate wide support from MaRS Innovation's community. To give back and show their appreciation, the campaign team hosted a reception at Sunnybrook Health Sciences Centre in the Louise Temerty Breast Cancer Centre on November 6, 2013. Present were several members of the Women's Art Association of Canada (WAAC) who donated 11 of the 15 artworks to the campaign. Also present was Dale Butterill, ... Read more

WaveCheck to Transform Chemotherapy Monitoring for Women with Breast Cancer

Indiegogo campaign to raise funds for North American clinical study during Breast Cancer Awareness Month; 12 artists donate 13 original works worth over $15,000 to support campaign Toronto, Canada (October 9, 2013) — WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer ... Read more

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor. Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money. XLV’s solution has ... Read more

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it - part of a growing trend of selling science to help shore up Canada's troubled health-care system. Tuesday's agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question. But the licensing deal with one of the world's biggest drug companies ... Read more